NAS10029,447+1.73%S&P7,638+1.14%GOLD$4,384−0.09%BTC$76,375+0.29%VIX15.44−12.82%live tape · as of 05:00 UTC
The Screen · Healthcare · Drug Manufacturers - General
Johnson & Johnson
JNJ · a US exchange · USD · Market cap $648.6B · 138,200 employees
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.
Screened 2026-09-08 · the tape above runs as of 05:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its distribution label.
Johnson & Johnson holds its Distribution at $269.12. The statistical read favours the buyers, held for 1 days.
As held on the ledger · 2026-09-08
Phase
Distribution · caution
Quantitative state
The statistical read favours the buyers, held for 1 days
Price at the screen
$269.12
Valuation
31.26 trailing · 21.87 forward price to earnings
Values screen
PASS· score 83.4
Beta
0.24
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
24.06%
Below 33%
Interest-bearing debt is just 24.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
0.20%
Below 33%
Cash held in interest-bearing accounts and securities is 0.2% of assets, under the one-third limit.
Pass
Receivables
18.52%
Below 49%
Money owed to the company is 18.5% of assets, under the 49% limit.
Pass
Revenue purity
1.12%
Below 5%
Only 1.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads OVERVALUED: it trades at roughly a 3% discount to our $275.88 fair value, strong competitive moat, 6.60% revenue growth.
Fair value range in USD, drawn from the 2026-09-08 screen. The gold marker is the market price at the same screen. A 2.5% margin of safety to the base estimate.
Third-party analyst targets: 22 covering, consensus Buy. The average target sits +4% from the screen price.
Reading the gap · Our model and the Street both land near today's price: fairly valued, with no strong edge either way.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-08 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Healthcare Giant With a Heart
Imagine a company that's been around for over a century, providing healthcare solutions to the world. Johnson & Johnson fits that description, a household name in healthcare products, from pharmaceuticals to medical devices. With a strong moat and a consistent 7% revenue growth, it stands out as a reliable player in this critical field. Our fair value sits just above the current price, signaling a modest margin of safety.
The numbers back up Johnson & Johnson's standout status. A forward P/E of 21.7x, a profit margin of 21%, and an impressive ROE of 26% all underscore its financial strength. The consensus among 22 analysts is a buy, with a median target price above our fair value, suggesting a continued bullish outlook.
However, it's not all rosy. Johnson & Johnson is currently rated as overvalued by our metrics. While the ethical screen is a pass, the forward P/E and current price suggest caution. The risk here is that you're paying a premium for a company with a strong track record, but the current valuation may not leave much room for error. Analysis, not advice.
The risks · The things to watch: as a drug manufacturers - general name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
JNJ trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-03Markup$267.37+1.5%Entry 6
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 1.5% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 56%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (24 analysts) rates it buy, with a mean price target of $253.
2026-08-03Markup$263.40+13.2%Entry 5
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 13.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 56%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (24 analysts) rates it buy, with a mean price target of $253.
2026-07-18Markup$232.77+0.0%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it A, carrying a low risk profile. Technically it is holding around 10% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 56%. Our forward projection puts the odds of a 10% gain over the next month near 14%. The street (24 analysts) rates it buy, with a mean price target of $253.
2026-07-15Markup$232.77+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows excellent risk-adjusted returns. It reported earnings in this window, a natural checkpoint for the thesis.
2026-07-03Markup$232.77+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markup$232.77Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
